Endocrinology: Strategic Biosimulation Services

Certara has broad expertise in endocrine diseases including diabetes, obesity, hypogonadism, and hypoparathyroidism. For example, our scientists supported more than 50 diabetes development programs for industry clients over the past eight years, from pre-clinical to Phase IV commercial strategy. Our consultants have addressed critical issues in trial design, dose selection, extrapolation from animal to human, and development strategy for the major classes of diabetes therapies. We performed 15 projects in 2012 including population dose-response and PK/PD analyses of efficacy and safety biomarker data, dose selection for renally impaired patients and long-term forecasting of HbA1c levels.

Our extensive knowledge and compilations of public data from the clinical and scientific literature for endocrine diseases provide a ready context for model-based meta-analysis to assess your compound's performance against competing therapies.

Number and types of projects:

  • 51 projects
  • Type - protein, small molecule, peptide
  • Mechanisms of action - rhPTH, DDPR Inhibitors, GKA (glucokinase activator), GLP-1R (non-peptide agonist of glucagon-like peptide 1 receptor), insulin products
  • Disease areas
    • Type 1 diabetes
    • Type 2 diabetes
    • Hypogonadism
    • Hypoparathyroidism
    • Obesity

By partnering with Certara Strategic Consulting, you can leverage the power of biosimulation technology to get your drug to market faster.